Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-04
2011-11-29
Weddington, Kevin E (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S023000, C514S549000
Reexamination Certificate
active
08067359
ABSTRACT:
Disclosed is a method and composition for nutritionally improving glucose and insulin balance in an individual. The invention further provides a method for treating a comorbidity of diabetes. In one embodiment, the invention provides a nutritional formulation comprising: a protein source; a fat source; and a carbohydrate source, wherein the protein source, the fat source, and the carbohydrate source are in a ratio of about 1:1:1, each comprising about one third of the total calories of the composition.
REFERENCES:
patent: 4614663 (1986-09-01), Rule
patent: 6140304 (2000-10-01), Sears et al.
patent: 2005/0002988 (2005-01-01), Mizumoto et al.
patent: 9873118 (1998-12-01), None
patent: 0 843 972 (1998-05-01), None
patent: 0 898 900 (1999-03-01), None
International Search Report and the Written Opinion dated Nov. 23, 2006, received in counterpart PCT Application No. PCT/US2006/012576 (22 pg).
Cheuvront, “The Zone Diet Phenomenon: A Closer Look at the Science behind the Claims,” Journal of the American College of Nutrition, vol. 22, No. 1, pp. 9-17 (2003).
Dansinger et al, “Comparison of the Atkins, Ornish, Weight Watchers, & Zone Diets for Weight Loss & Heart Disease Risk Reduction,” JAMA, vol. 293, No. 1, pp. 43-53 (Jan. 5, 2005).
Hein et al., “Linoleic-acid-enriched diet. . .,” American Society of Clinical Nutrition, vol. 49, No. 3, pp. 448-456 (Mar. 1, 1989).
Simopoulos, “Is Insulin Resistance Influenced By Dietary Linoleic Acide & Trans Fatty Acids!,” Free Radical Biology & Medicine, vo. 17, No. 4, pp. 367-370 (Oct. 1, 1994).
“Glucose Transport Expression Promoter for Preventing & Improving Diabetes, Insulinemia & Insulin Resistance, Comprises Catechin As Active Ingredient,” Abstract Only (2003).
Cefalu et al., “Oral Chromium Picolinate Improves Carbohydrate & Lipid Metabolism. . . ,” American Society of Clinical Nutrition, vol. 132, pp. 1107-1114 (2002).
Greene et al., “Alpha-Lipoic Acid Prevents the Development of Glucose-Induced Insulin Resistance in 3T3-L1 Adipocytes. . .,” Metabolism, vol. 50, No. 9, pp. 1063-1069, (Sep. 2001).
Qin et al., “Cinnamon Extract Prevents the Insulin Resistance Induced by a High-Fructose Diet,” Hromon & Metabolic Research, vol. 36, No. 2, pp. 119-125 (Feb. 2004).
Clarke, “Polyunsatured Fatty Acid Regulation of Gene Transcription. . .,” American Society of Nutritional Sciences, vol. 131, pp. 1129-1132 (2001).
Timar et al., “Metabolic syndrom X: a review,” Canadian Journal of Cardiology, vol. 16, no. 6, pp. 779-789 (Jun. 2000).
Howard et al., “Insulin Sensitivity and Atherosclerosis,” American Health Association, vol. 93, pp. 1809-1817 (1996).
Bommartini et al., “Guar-Carob Bean Association in the Control of Post-Prandial Hyperglycemia,” Societa Italiana di Gerontologia e Geriatria, vol. 33, no. 6, pp. 497-504 (1985).
Biolo Gianni
Falk Anne L.
Greenberg Norman Alan
Hayes Kenneth C.
Troup John P.
K&L Gates LLP
Nestec S.A.
Weddington Kevin E
LandOfFree
Composition for nutritionally improving glucose control and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for nutritionally improving glucose control and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for nutritionally improving glucose control and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281904